Lower Dose Immunotherapy Shows Promise in Melanoma Treatment

New research suggests that a lower dose of immunotherapy, a treatment used for advanced melanoma, may be more effective and cause fewer side effects than the standard, higher dose. The findings, published in the Journal of the National Cancer Institute, challenge conventional wisdom in oncology, which often focuses on increasing dosage to maximize treatment impact.

The Standard Treatment and Its Challenges

Currently, the established treatment for advanced melanoma combines nivolumab and ipilimumab at specific doses. However, this regimen is known for causing significant and sometimes life-threatening side effects. These adverse reactions are largely attributed to ipilimumab, the costlier component of the combination therapy.

Swedish Approach and Research Findings

Due to the severity of side effects, doctors in Sweden have increasingly adopted a strategy of reducing the dose of ipilimumab. This approach is facilitated by greater flexibility in dosage selection compared to many other countries, where reimbursement policies often restrict doctors to approved doses. A retrospective study involving nearly 400 patients with advanced, inoperable malignant melanoma revealed significant benefits from the lower-dose approach.

Improved Outcomes with Lower Dosage

The study demonstrated that 49% of patients receiving the lower dose of ipilimumab experienced a measurable response to treatment, compared to 37% in the group receiving the standard dose. Progression-free survival – the time patients lived without their disease worsening – reached a median of nine months in the lower-dose group, significantly longer than the three months observed in the standard-dose group. Perhaps most notably, overall survival was substantially improved, with a median of 42 months for the reduced-dose group versus 14 months for those on the traditional regimen.

Reduced Side Effects

The lower dose as well led to a substantial reduction in severe side effects. 31% of patients receiving the lower dose experienced serious complications, compared to 51% of those on the conventional regimen. Researchers believe this allows more patients to continue treatment for a longer duration, contributing to improved outcomes and longer survival.

Study Details and Future Research

While the study accounted for factors like age and tumor stage, and showed improved outcomes even after adjustment, it’s significant to note that it was a retrospective observational study. This means it cannot definitively prove a direct cause-and-effect relationship. Further research, including prospective clinical trials, is needed to confirm these findings and establish the lower dose as a new standard of care.

The project was carried out in partnership with the Sahlgrenska Comprehensive Cancer Center at Sahlgrenska University Hospital and was funded by the Cancer Foundation, Region Stockholm, and the Radiumhemmet Research Fund.

Key Takeaways

• Lowering the dose of ipilimumab in combination with nivolumab may improve treatment outcomes for advanced melanoma.
• Reduced dosage is associated with fewer severe side effects, potentially allowing for longer treatment duration.
• The findings suggest a need to re-evaluate conventional dosage strategies in immunotherapy.
• Further research is necessary to confirm these results and establish new treatment guidelines.

Reference: Björkström, K., Liu, C., Fager, A., Liu, L. L., Ny, L., & Helgadottir, H. (2025). Evaluation of the flipped dose NIVO3+IPI1 in patients with advanced unresectable melanoma. JNCI: Journal of the National Cancer Institute, djaf327. https://doi.org/10.1093/jnci/djaf327